1Newby JC, Hern RPA. Leek RD,et al. Immunohistochemical assay for EGFR on paraffinembedded sections: validation against ligand- binding assay and clinical relecance in breast cancer. Br J Can,1995,71:1237.
2Fitzpatrick SL,Brightwell J, Wittliff JL, et al. Epidermal growth factor binding by hreas tumor biopsies and relationship to estrogen receptor and progestin receptor levels. Can Res, 1984, 44:3448.
3Hainsworth PJ, Henderson MA,Stillwell RG, et al. Comprision of EGFR,C-erbB2 product Immunohistochemistry as prognostic markers in breast cancer. Eur J Surg Oncol ,1991,17:9.
4Bolufer p, Miralles F. Rodriguez A. et al. EGFR in human breast:correlation with cytosolic and nuclear ER and with biological and histological tumor characteristics.Eur J Cancer,1990,26:283.
5Iwaya K,Tsuda H,Hiraide H,et al. Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Can Res,1991,82:835.
6Lewis S, Locker A ,Todd JH, et al. Expression of EGFR in breast cancer. J Clin Pathol ,1990, 43:385.
7Levine AJ, Momand J, Finlay CA. The p53 tumor suppress or gene. Nature, 1991,351:453.
8Moll UM,Rioa G,Leviue AJ,et al. Two distinct mechanisms alter p55 in breast cancer :mutation and nuclear exclusion, Pro Natl Acad Sci U. S.A,1992,89:7262.
9Allred D,Clark M, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical out come in node-negative breast cancer. J Natl Cancer Inst, 1993,85:200.
